What is the appropriate dosing regimen of biperiden for drug‑induced parkinsonism caused by citalopram?

Biperiden Should Not Be Used for Citalopram-Induced Parkinsonism

The primary management strategy for citalopram-induced parkinsonism is to discontinue or reduce the dose of citalopram, not to add biperiden. Citalopram is an SSRI that can cause drug-induced parkinsonism (DIP) through mechanisms distinct from typical antipsychotic-induced extrapyramidal symptoms, and anticholinergic agents like biperiden are not indicated for this condition 1, 2.

Why Biperiden Is Not Appropriate

The available guideline evidence specifically addresses anticholinergic use (including biperiden) in the context of antipsychotic-induced parkinsonism, not SSRI-induced parkinsonism. The 2002 Alzheimer's guidelines explicitly state to "avoid use of benztropine (Cogentin) or trihexyphenidyl (Artane)" when extrapyramidal symptoms occur with typical antipsychotics 3. While biperiden is not specifically named, it belongs to the same anticholinergic class and carries similar concerns.

More importantly, the 2018 ESMO delirium guidelines recommend anticholinergics for acute dystonia associated with antipsychotic therapy, but for parkinsonism they suggest: lowering the antipsychotic dosage, switching to another agent, or treating with an anticholinergic 4. The APA 2020 schizophrenia guidelines similarly list anticholinergics as one option among several for antipsychotic-induced parkinsonism 5.

The Correct Management Approach

Step 1: Discontinue or reduce citalopram 1, 2, 6

• Full recovery from citalopram-induced parkinsonism typically occurs after drug discontinuation
• The case report demonstrates complete resolution with UPDRS motor score improving from presumed high baseline to 4/108 after stopping citalopram 1

Step 2: Taper citalopram appropriately 7

• Gradually reduce the dose rather than abrupt cessation to avoid discontinuation syndrome
• If intolerable symptoms occur, resume the previous dose and decrease more gradually

Step 3: Monitor for symptom resolution 2, 6

• DIP typically improves within weeks to months after discontinuing the offending agent
• If symptoms persist beyond 6 months, consider that the patient may have had underlying prodromal Parkinson's disease that was "unmasked" by citalopram 6, 8

Step 4: Consider ancillary testing if symptoms persist 2, 6, 8

• DaTscan (ioflupane-123 SPECT) can differentiate true Parkinson's disease from DIP
• Skin biopsy for alpha-synuclein deposits may be helpful in ambiguous cases

Critical Pitfalls to Avoid

Do not add anticholinergics prophylactically or routinely 9, 2. Research evidence clearly states that "prophylactic treatment with anticholinergics is not indicated" for DIP 2. The routine use of prophylactic anticholinergics is "not recommended and is clearly contraindicated in the elderly" 9.

Do not confuse SSRI-induced parkinsonism with antipsychotic-induced extrapyramidal symptoms. While biperiden has demonstrated efficacy for neuroleptic-induced EPS 10, 11, there is no evidence supporting its use for SSRI-induced parkinsonism. The pathophysiology differs: antipsychotics block dopamine D2 receptors directly, while SSRIs like citalopram may affect dopamine through serotonergic mechanisms 1.

Anticholinergics worsen cognition and carry significant risks, particularly in older adults. The 2025 INTEGRATE schizophrenia guidelines emphasize minimizing anticholinergic burden to reduce cognitive impairment 12. Given that citalopram itself has minimal anticholinergic activity 7, adding biperiden would unnecessarily increase this burden.

If Parkinsonism Must Be Treated Pharmacologically

Only consider symptomatic treatment if:

1. Citalopram cannot be discontinued due to severe depression
2. Dose reduction is insufficient
3. Switching to another antidepressant is not feasible

In such rare circumstances, amantadine (100 mg twice daily) would be preferred over biperiden 10, 9. Research shows amantadine is equally effective as anticholinergics for parkinsonian symptoms but is "better tolerated in elderly patients" 9. However, this should be considered only after exhausting the primary strategy of discontinuing or switching the causative agent 2, 6.